Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30

Benzinga · 05/07 16:02
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $32 to $30.